Human challenge studies: A review of adequacy of reporting methods and results

Future Microbiology

Volumn 7, Issue 4, 2012, Pages 481-495

  Kalil, Jennifer A ^a   Halperin, Scott A ^a   Langley, Joanne M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

experimental infection; human challenge; knowledge translation; reporting; systematic review

Indexed keywords

ADENOVIRUS; ADVERSE OUTCOME; CAMPYLOBACTER JEJUNI; CANDIDA ALBICANS; CORONAVIRUS; CRYPTOSPORIDIUM; CYCLOSPORA CAYETANENSIS; CYTOMEGALOVIRUS; DENGUE VIRUS; ESCHERICHIA COLI; ETHICS; FOLLOW UP; GIARDIA LAMBLIA; HAEMOPHILUS DUCREYI; HELICOBACTER PYLORI; HEPATITIS A VIRUS; HOSPITAL PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFLUENZA VIRUS; INFORMED CONSENT; LISTERIA MONOCYTOGENES; MASS SCREENING; METHODOLOGY; MODEL; NEISSERIA GONORRHOEAE; NONHUMAN; NOROVIRUS; OUTCOME ASSESSMENT; OUTPATIENT; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; RHINOVIRUS; RISK ASSESSMENT; SALMONELLA TYPHI; SARCOPTES SCABIEI; SHIGELLA FLEXNERI; STREPTOCOCCUS MUTANS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRONGYLOIDES; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); VACCINATION; VIBRIO CHOLERAE; VIRUS TRANSMISSION;

CLINICAL TRIALS AS TOPIC; HUMAN EXPERIMENTATION; HUMANS; RESEARCH DESIGN;

EID: 84858987735     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.12.15     Document Type: Review

References (196)

1. Miller FG, Grady C. The ethical challenge of infection-inducing challenge experiments. Clin. Infect. Dis. 33(7), 1028-1033 (2001).
2. Rosenbaum JR, Sepkowitz KA. Infectious disease experimentation involving human volunteers. Clin. Infect. Dis. 34(7), 963-971 (2002).
3. Moher D, Hopewell S, Schulz KF et al.; for the CONSORT Group. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trial. BMJ 340, C869 (2010).
4. Crowther M, Lim W, Crowther MA. Systematic review and meta-analysis methodology. Blood 116(17), 3140-3146 (2010).
5. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354(9193), 1896-1900 (1999).
6. Aoki FY, Reed SE, Craig JW, Tyrrell DA, Lees LJ. Effect of a polynucleotide interferon inducer of fungal origin on experimental rhinovirus infection in humans. J. Infect. Dis. 137(1), 82-86 (1978).
7. Boggs JD, Melnick JL, Conrad ME, Felsher BF. Viral hepatitis: clinical and tissue culture studies. JAMA 214(6), 1041-1046 (1970).
8. Melnick JL, Boggs JD. Human volunteer and tissue culture studies of viral hepatitis. Can. Med. Assoc. J. 106(Suppl.), 461-467 (1972).
9. Pachuta DM, Togo Y, Hornick RB, Schwartz AR, Tominaga S. Evaluation of isoprinosine in experimental human rhinovirus infection. Antimicrob. Agents Chemother. 5(4), 403-408 (1974).
10. Reichman RC, Pons VG, Murphy BR, Caplan EA, Dolin R. Cell-mediated cytotoxicity following influenza infection and vaccination in humans. J. Med. Virol. 4(1), 1-14 (1979).
11. Togo Y, Schwartz AR, Hornick RB. Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection. Antimicrob. Agents Chemother. 4(6), 612-616 (1973).
12. Waldman RH, Ganguly R. Effect of CP-20, 961, an interferon inducer, on upper respiratory tract infections due to rhinovirus type 21 in volunteers. J. Infect. Dis. 138(4), 531-535 (1978).
13. Al-Nakib W, Higgins PG, Barrow GI et al. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob. Agents Chemother. 33(4), 522-525 (1989).
14. Al-Nakib W, Higgins PG, Barrow I, Batstone G, Tyrrell DAJ. Prophylaxis and treatment of rhinovirus colds with zinc gluconate lozenges. J. Antimicrob. Chemother. 20(6), 893-901 (1987).
15. Al-Nakib W, Higgins PG, Barrow I, Tyrrell DAJ, Lenox-Smith I, Ishitsuka H. Intranasal chalcone, ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J. Antimicrob. Chemother. 20(6), 887-892 (1987).
16. Al-Nakib W, Willman J, Higgins PG, Tyrrell DA, Shepherd WM, Freestone DS. Failure of intranasally administered 4′, 6-dichloroflavan to protect against rhinovirus infection in man. Arch. Virol. 92, 255-260 (1987).
17. Anderson MJ, Higgins PG, Davis LR et al. Experimental parvoviral infection in humans. J. Infect. Dis. 152(2), 257-265 (1985).
18. Bernstein DI, Ziegler JM, Ward RL. Rotavirus fecal IgA antibody response in adults challenged with human rotavirus. J. Med. Virol. 20(4), 297-304 (1986).
19. Black RE, Levine MM, Clements ML. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 155(6), 1260-1265 (1987).
20. Black RE, Levine MM, Clements ML, Hughes TP, Blaser MJ. Experimental Campylobacter jejuni infection in humans. J. Infect. Dis. 157(3), 472-479 (1988).
21. Carroll SM, Grove DI. Experimental infection of humans with Ancylostoma ceylanicum: clinical, parasitological, haematological and immunological findings. Trop. Geogr. Med. 38(1), 38-45 (1986).
22. Chulay JD, Schneider I, Cosgriff TM. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am. J. Trop. Med. Hyg. 35(1), 66-68 (1986).
23. Dick EC, Hossain SU, Mink KA et al. Interruption of transmission of rhinovirus colds among human volunteers using virucidal paper handkerchiefs. J. Infect. Dis. 153(2), 352-356 (1986).
24. Doyle WJ, McBride T, Skoner DP, Maddern BR, Gwaltney JM Jr, Uhrin M. A double-blind, placebo-controlled clinical trial of the effect of chlorpheniramine on the response of the nasal airway, middle ear and eustachian tube to provocative rhinovirus challenge. Pediatr. Infect. Dis. J. 7(3), 229-240 (1988).
25. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159(6), 1126-1128 (1989).
26. Estes SA, Kummel B, Arlian L. Experimental canine scabies in humans. J. Am. Acad. Dermatol. 9(3), 397-401 (1983).
27. Gaffey MJ, Gwaltney JM Jr, Dressler WE. Intranasally administered atropine methonitrate treatment of experimental rhinovirus colds. Am. Rev. Respir. Dis. 135(1), 241-244 (1987).
28. Gahnberg L, Krasse B. Salivary immunoglobulin A antibodies and recovery from challenge of Streptococcus mutans after oral administration of Streptococcus mutans vaccine in humans. Infect. Immun. 39(2), 514-519 (1983).
29. Gwaltney JM Jr, Moskalski PB, Hendley JO. Interruption of experimental rhinovirus transmission. J. Infect. Dis. 142(6), 811-815 (1980).
30. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. Ribavirin treatment of experimental respiratory syncytial viral infection: a controlled double-blind study in young adults. JAMA 249(19), 2666-2670 (1983).
31. Halperin SA, Eggleston PA, Hendley JO, Suratt PM, Groschel DH, Gwaltney JM Jr. Pathogenesis of lower respiratory tract symptoms in experimental rhinovirus infection. Am. Rev. Respir. Dis. 128(5), 806-810 (1983).
32. Hayden FG, Gwaltney JM Jr. Intranasal interferon-alpha 2 for prevention of rhinovirus infection and illness. J. Infect. Dis. 148(3), 543-550 (1983).
33. Hayden FG, Gwaltney JM Jr. Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J. Infect. Dis. 150(2), 174-180 (1984).
34. Hayden FG, Gwaltney JM Jr, Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res. 9(4), 233-247 (1988).
35. Hayden FG, Zylidnikov DM, Iljenko VI, Padolka YV. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res. 2(3), 147-153 (1982).
36. Higgins PG, Al-Nakib W, Barrow GI, Tyrrell DA. Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers. J. Interferon Res. 8(5), 591-596 (1988).
37. Higgins PG, Phillpotts RJ, Scott GM. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob. Agents Chemother. 24(5), 713-715 (1983).
38. Hsia J, Sztein MB, Naylor PH, Simon GL, Goldstein AL, Hayden FG. Modulation of thymosin alpha1 and thymosin beta4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds. Lymphokine Res. 8(4), 383-391 (1989).
39. Kapikian AZ, Wyatt RG, Levine MM et al. Oral administration of human rotavirus to volunteers: indication of illness and correlates of resistance. J. Infect. Dis. 147(1), 95-106 (1983).
40. Levandowski RA, Ou DW, Jackson GG. Acute-phase decrease of T lymphocyte subsets in rhinovirus infection. J. Infect. Dis. 153(4), 743-748 (1986).
41. Levine MM, Black RE, Clements ML et al. Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect. Immun. 43(2), 515-522 (1984).
42. Levine MM, Ristaino P, Marley G et al. Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect. Immun. 44(2), 409-420 (1984).
43. Leyden JJ, Stewart R, Kligman AM. Experimental infections with group A streptococci in humans. J. Invest. Dermatol. 75(2), 196-201 (1980).
44. McMichael AJ, Gotch FM, Noble GR, Beare PAS. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309(1), 13-17 (1983).
45. Meschievitz CK, Schultz SB, Dick EC. A model for obtaining predictable natural transmission of rhinoviruses in human volunteers. J. Infect. Dis. 150(2), 195-201 (1984).
46. Naclerio RM, Proud D, Kagey-Sobotka A, Lichtenstein LM, Hendley JO, Gwaltney JM Jr. Is histamine responsible for the symptoms of rhinovirus colds? A look at the inflammatory mediators following infection. Pediatr. Infect. Dis. J. 7(3), 218-222 (1988).
47. Nash TE, Herrington DA, Losonsky GA, Levine MM. Experimental human infections with Giardia lamblia. J. Infect. Dis. 156(6), 974-984 (1987).
48. Okuno Y, Fukunaga T, Tadano M. Serological studies on volunteers inoculated experimentally with a dengue virus strain in 1943. Biken J. 26(4), 161-163 (1983).
49. Phillpotts RJ, Higgins PG, Willman JS. Intranasal lymphoblastoid interferon ('wellferon') prophylaxis against rhinovirus and influenza virus in volunteers. J. Interferon Res. 4(4), 535-541 (1984).
50. Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Lenox-Smith I. Evaluation of the antirhinovirus chalcone ro 09-0415 given orally to volunteers. J. Antimicrob. Chemother. 14(4), 403-409 (1984).
51. Phillpotts RJ, Scott GM, Higgins PG, Wallace J, Tyrell DAJ, Gauci CL. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha2. Antiviral Res. 3(2), 121-136 (1983).
52. Phillpotts RJ, Wallace J, Tyrrell DAJ, Freestone DS, Shepherd WM. Failure of oral 4′,6-dichloroflavan to protect against rhinovirus infection in man. Arch. Virol. 75(1-2), 115-121 (1983).
53. Phillpotts RJ, Wallace J, Tyrrell DAJ, Tagart VB. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob. Agents Chemother. 23(5), 671-675 (1983).
54. Plotkin SA, Starr SE, Friedman HM, Gönczöl E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J. Infect. Dis. 159(5), 860-865 (1989).
55. Potter CW, Jennings R, Clark A, Ali M. Interference following dual inoculation with influenza A (H3N2) and (H1N1) viruses in ferrets and volunteers. J. Med. Virol. 11(1), 77-86 (1983).
56. Quinnan GV Jr, Delery M, Rook AH et al. Comparative virulence and immunogenicity of the towne strain and a nonattenuated strain of cytomegalovirus. Ann. Intern. Med. 101(4), 478-483 (1984).
57. Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E related strains. J. Med. Virol. 13(2), 179-192 (1984).
58. Samo TC, Greenberg SB, Palmer JM et al. Intranasally applied recombinant leukocyte A interferon in normal volunteers. II. Determination of minimal effective and tolerable dose. J. Infect. Dis. 150(2), 181-188 (1984).
59. Sperber SJ, Levine PA, Innes DJ, Mills SE, Hayden FG. Tolerance and efficacy of intranasal administration of recombinant beta serine interferon in healthy adults. J. Infect. Dis. 158(1), 166-175 (1988).
60. Turner RB, Winther B, Hendley JO, Mygind N, Gwaltney JM. Sites of virus recovery and antigen detection in epithelial cells during experimental rhinovirus infection. Acta Otolaryngol. 413(Suppl.), 9-14 (1984).
61. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR, Schiff GM. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J. Infect. Dis. 154(5), 871-880 (1986).
62. Winther B, Farr B, Turner RB, Hendley JO, Gwaltney JM, Mygind N. Histopathologic examination and enumeration of polymorphonuclear leukocytes in the nasal mucosa during experimental rhinovirus colds. Acta Otolaryngol. Suppl. 413, 19-24 (1984).
63. Winther B, Gwaltney JM Jr, Mygind N, Turner RB, Hendley JO. Sites of rhinovirus recovery after point inoculation of the upper airway. JAMA 256(13), 1763-1767 (1986).
64. Al-Tawfiq JA, Palmer KL, Chen C-Y et al. Experimental infection of human volunteers with Haemophilus ducreyi does not confer protection against subsequent challenge. J. Infect. Dis. 179(5), 1283-1287 (1999).
65. Al-Tawfiq JA, Thornton AC, Katz BP et al. Standardization of the experimental model of Haemophilus ducreyi infection in human subjects. J. Infect. Dis. 178(6), 1684-1687 (1998).
66. Bardin PG, Fraenkel DJ, Sanderson G, Lampe F, Holgate ST. Lower airways inflammaton/response during rhinovirus colds. Int. Arch. Allergy Immunol. 107(1-3), 127-129 (1995).
67. Bjornson AB, Mellencamp MA, Schiff GM. Complement is activated in the upper respiratory tract during influenza virus infection. Am. Rev. Respir. Dis. 143(5 Pt 1), 1062-1066 (1991).
68. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 43(7), 1616-1620 (1999).
69. Calhoun WJ, Dick EC, Schwartz LB, Busse WW. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J. Clin. Invest. 94(6), 2200-2208 (1994).
70. Calhoun WJ, Swenson CA, Dick EC, Schwartz LB, Lemanske RF Jr, Busse WW. Experimental rhinovirus 16 infection potentiates histamine release after antigen bronchoprovocation in allergic subjects. Am. Rev. Respir. Dis. 144(6), 1267-1273 (1991).
71. Callow KA, Parry HF, Sergeant M, Tyrrell DAJ. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105(2), 435-446 (1990).
72. Chappell CL, Okhuysen PC, Sterling CR, Wang C, Jakubowski W, Dupont HL. Infectivity of Cryptosporidium parvum in healthy adults with pre- existing anti-C. parvum serum immunoglobulin G. Am. J. Trop. Med. Hyg. 60(1), 157-164 (1999).
73. Church LWP, Le TP, Bryan JP et al. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J. Infect. Dis. 175(4), 915-920 (1997).
74. Clements ML, Belshe RB, King J et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J. Clin. Microbiol. 29(6), 1175-1182 (1991).
75. Clements ML, Snyder MH, Sears SD, Maassab HF, Murphy BR. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J. Infect. Dis. 161(5), 869-877 (1990).
76. Cohen MS, Cannon JG. Human experimentation with Neisseria gonorrhoeae: progress and goals. J. Infect. Dis. 179(Suppl. 2), S375-S379 (1999).
77. Cohen MS, Cannon JG, Jerse AE, Charniga LM, Isbey SF, Whicker LG. Human experimentation with Neisseria gonorrhoeae: rationale, methods, and implications for the biology of infection and vaccine development. J. Infect. Dis. 169(3), 532-537 (1994).
78. Coster TS, Hoge CW, VanDeVerg LL et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun. 67(7), 3437-3443 (1999).
79. Donnenberg MS, Tacket CO, Losonsky G et al. Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge. Infect. Immun. 66(1), 52-58 (1998).
80. Doyle WJ, Skoner DP, Fireman P et al. Rhinovirus 39 infection in allergic and nonallergic subjects. J. Allergy Clin. Immunol. 89(5), 968-978 (1992).
81. Dumler JS, Wisseman CL Jr, Fiset P, Clements ML. Cell-mediated immune responses of adults to vaccination, challenge with Rickettsia rickettsii, or both. Am. J. Trop. Med. Hyg. 46(2), 105-115 (1992).
82. DuPont HL, Chappell CL, Sterling CR, Okhuysen PC, Rose JB, Jakubowski W. The infectivity of Cryptosporidium parvum in healthy volunteers. N. Engl. J. Med. 332(13), 855-859 (1995).
83. Farr BM, Gwaltney JM Jr, Hendley JO et al. A randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J. Infect. Dis. 162(5), 1173-1177 (1990).
84. Freedman DO. Experimental infection of human subjects with Strongyloides species. Rev. Infect. Dis. 13(6), 1221-1226 (1991).
85. Glynn JR, Hornick RB, Levine MM, Bradley DJ. Infecting dose and severity of typhoid: analysis of volunteer data and examination of the influence of the definition of illness used. Epidemiol. Infect. 115(1), 23-30 (1995).
86. Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6), 1576-1585 (1995).
87. Graham DY, Evans DG. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers. Rev. Infect. Dis. 12(Suppl. 1), S68-S72 (1990).
88. Graham NMH, Burrell CJ, Douglas RM, Debelle P, Davies L. Adverse effects of aspirin, acetaminophen, and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. J. Infect. Dis. 162(6), 1277-1282 (1990).
89. Grunberg K, Timmers MC, De Klerk EPA, Dick EC, Sterk PJ. Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma. Am. J. Respir. Crit. Care Med. 160(4), 1375-1380 (1999).
90. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163(4), 693-698 (1991).
91. Harpaz R, Edelman R, Wasserman SS, Levine MM, Davis JR, Sztein MB. Serum cytokine profiles in experimental human malaria: relationship to protection and disease course after challenge. J. Clin. Invest. 90(2), 515-523 (1992).
92. Harris JM 2nd, Gwaltney JM Jr. Incubation periods of experimental rhinovirus infection and illness. Clin. Infect. Dis. 23(6), 1287-1290 (1996).
93. Hayden FG, Andries K, Janssen PAJ. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob. Agents Chemother. 36(4), 727-732 (1992).
94. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 275(4), 295-299 (1996).
95. Hayden FG, Treanor JJ, Fritz RS et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282(13), 1240-1246 (1999).
96. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob. Agents Chemother. 38(5), 1178-1181 (1994).
97. Hendley JO, Abbott RD, Beasley PP, Gwaltney JM Jr. Effect of inhalation of hot humidified air on experimental rhinovirus infection. JAMA 271(14), 1112-1113 (1994).
98. Hsia J, Goldstein AL, Simon GL, Sztein M, Hayden FG. Peripheral blood mononuclear cell interleukin-2 and interferon-gamma production, cytotoxicity, and antigen-stimulated blastogenesis during experimental rhinovirus infection. J. Infect. Dis. 162(3), 591-597 (1990).
99. Heppner DG, Gordon DM, Gross M et al. Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J. Infect. Dis. 174(2), 361-366 (1996).
100. Higgins PG, Barrow GI, Tyrrell DAJ, Snell NJC, Jones K, Jolley WB. A study of the efficacy of the immunomodulatory compound 7-thia-8-oxoguanosine in coronavirus 229E infections in human volunteers. Antiviral Chem. Chemother. 2(1), 61-64 (1991).
101. Johannsen DB, Johnston DM, Koymen HO, Cohen MS, Cannon JG. A Neisseria gonorrhoeae immunoglobulin A1 protease mutant is infectious in the human challenge model of urethral infection. Infect. Immun. 67(6), 3009-3013 (1999).
102. Johnson PC, Mathewson JJ, DuPont HL, Greenberg HB. Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J. Infect. Dis. 161(1), 18-21 (1990).
103. Keitel WA, Couch RB, Cate TR, Six HR, Baxter BD. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J. Infect. Dis. 161(1), 22-26 (1990).
104. Kotloff KL, Herrington DA, Hale TL et al. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infect. Immun. 60(6), 2218-2224 (1992).
105. Kotloff KL, Losonsky GA, Nataro JP et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 13(5), 495-502 (1995).
106. Kotloff KL, Nataro JP, Losonsky GA. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 13(16), 1488-1494 (1995).
107. Losonsky GA, Tacket CO, Wasserman SS, Kaper JB, Levine MM. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection. Infect. Immun. 63(2), 729-733 (1993).
108. Losonsky GA, Yunyongying J, Lim V et al. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64(1), 10-15 (1996).
109. Mackowiak PA, Wasserman SS, Levine MM. An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis. J. Infect. Dis. 166(5), 1181-1184 (1992).
110. Morris JG Jr, Losonsky GE, Johnson JA et al. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers. J. Infect. Dis. 171(4), 903-908 (1995).
111. Ockenhouse CF, Sun P-F, Lanar DE et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a poxvectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177(6), 1664-1673 (1998).
112. Okhuysen PC, Chappell CL, Crabb J, Valdez LM, Douglass ET, DuPont HL. Prophylactic effect of bovine anti-Cryptosporidium hyperimmune colostrum immunoglobulin healthy volunteers challenged with Cryptosporidium parvum. Clin. Infect. Dis. 26(6), 1324-1329 (1998).
113. Palmer KL, Thornton AC, Fortney KR, Hood AF, Munson RS Jr, Spinola SM. Evaluation of an isogenic hemolysin-deficient mutant in the human model of Haemophilus ducreyi infection. J. Infect. Dis. 178(1), 191-199 (1998).
114. Ramsey KH, Schneider H, Kuschner RA, Trofa AF, Cross AS, Deal CD. Inflammatory cytokine response to experimental human infection with Neisseria gonorrhoeae. Ann. NY Acad. Sci. 730, 322-325 (1994).
115. Ramsey KH, Schneider H, Cross AS et al. Inflammatory cytokines produced in response to experimental human gonorrhea. J. Infect. Dis. 172(1), 186-191 (1995).
116. Sack DA, Tacket CO, Cohen MB et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect. Immun. 66(5), 1968-1972 (1998).
117. Schneider H, Schmidt KA, Skillman DR et al. Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC. J. Infect. Dis. 173(6), 1422-1427 (1996).
118. Sperber SJ, Hendley JO, Hayden FG, Riker DK, Sorrentino JV, Gwaltney JM Jr. Effects of naproxen on experimental rhinovirus colds. A randomized, double-blind, controlled trial. Ann. Intern. Med. 117(1), 37-41 (1992).
119. Spinola SM, Wild LM, Apicella MA, Gaspari AA, Campagnari AA. Experimental human infection with Haemophilus ducreyi. J. Infect. Dis. 169(5), 1146-1150 (1994).
120. Stone AA, Bovbjerg DH, Neale JM et al. Development of common cold symptoms following experimental rhinovirus infection is related to prior stressful life events. Behav. Med. 18(3), 115-120 (1992).
121. Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am. J. Trop. Med. Hyg. 47(3), 276-283 (1992).
122. Tacket CO, Kotloff KL, Losonsky G et al. Volunteer studies investigating the safety and efficacy of live oral El Tor Vibrio cholerae O1 vaccine strain CVD 111. Am. J. Trop. Med. Hyg. 56(5), 533-537 (1997).
123. Tacket CO, Losonsky G, Livio S, Edelman R, Crabb J, Freedman D. Lack of prophylactic efficacy of an enteric-coated bovine hyperimmune milk product against enterotoxigenic Escherichia coli challenge administered during a standard meal. J. Infect. Dis. 180(6), 2056-2059 (1999).
124. Tacket CO, Losonsky G, Nataro JP et al. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166(4), 837-841 (1992).
125. Tacket CO, Moseley SL, Kay B, Losonsky G, Levine MM. Challenge studies in volunteers using Escherichia coli strains with diffuse adherence to HEp-2 cells. J. Infect. Dis. 162(2), 550-552 (1990).
126. Treanor JJ, Roth FK, Betts RF. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J. Clin. Microbiol. 28(3), 596-599 (1990).
127. Turner BW, Cail WS, Hendley JO et al. Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. J. Allergy Clin. Immunol. 90(3 Pt 2), 474-478 (1992).
128. Turner RB, Wecker MT, Pohl G et al. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 281(19), 1797-1804 (1999). Good description of challenge virus and evaluation of illness severity for rhinovirus human challenge.
129. Ward RL, Bernstein DI, Knowlton DR et al. Prevention of surface-to-human transmission of rotaviruses by treatment with disinfectant spray. J. Clin. Microbiol. 29(9), 1991-1996 (1991).
130. Ward RL, Bernstein DI, Shukla R et al. Protection of adults rechallenged with a human rotavirus. J. Infect. Dis. 161(3), 440-445 (1990).
131. Youngner JS, Treanor JJ, Betts RF, Whitaker-Dowling P. Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans. J. Clin. Microbiol. 32(3), 750-754 (1994).
132. Zhu Z, Tang W, Gwaltney JM, Wu Y, Elias JA. Rhinovirus stimulation of interleukin-8 in vivo and in vitro: Role of NF-kappaB. Am. J. Physiol. Lung Cell Mol. Physiol. 273(4 Pt 1), L814-L824 (1997).
133. Alfano-Sobsey EM, Eberhard ML, Seed JR et al. Human challenge pilot study with Cyclospora cayetanensis. Emerg. Infect. Dis. 10(4), 726-728 (2004).
134. Al-Tawfiq J, Harezlak J, Katz BP, Spinola SM. Cumulative experience with Haemophilus ducreyi 35000 in the human model of experimental infection. Sex. Transm. Dis. 27(2), 111-114 (2000).
135. Al-Tawfiq JA, Bauer ME, Fortney KR et al. A pilus-deficient mutant of Haemophilus ducreyi is virulent in the human model of experimental infection. J. Infect. Dis. 181(3), 1176-1179 (2000).
136. Al-Tawfiq JA, Fortney KR, Katz BP, Hood AF, Elkins C, Spinola SM. An isogenic hemoglobin receptor-deficient mutant of Haemophilus ducreyi is attenuated in the human model of experimental infection. J. Infect. Dis. 181(3), 1049-1054 (2000).
137. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70(7), 3592-3601 (2002).
138. Atmar RL, Opekun AR, Gilger MA et al. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14(10), 1553-1557 (2008).
139. Bong CTH, Fortney KR, Katz BP et al. A superoxide dismutase C mutant of Haemophilus ducreyi is virulent in human volunteers. Infect. Immun. 70(3), 1367-1371 (2002).
140. Buchman CA, Doyle WJ, Pilcher O, Gentile DA, Skoner DP. Nasal and otologic effects of experimental respiratory syncytial virus infection in adults. Am. J. Otolaryngol. Head Neck Med. Surg. 23(2), 70-75 (2002).
141. Chappell CL, Okhuysen PC, Langer-Curry R et al. Cryptosporidium hominis: experimental challenge of healthy adults. Am. J. Trop. Med. Hyg. 75(5), 851-857 (2006).
142. Christiansen SC, Eddleston J, Bengtson SH et al. Experimental rhinovirus infection increases human tissue kallikrein activation in allergic subjects. Int. Arch. Allergy Immunol. 147(4), 299-304 (2008).
143. Cohen MB, Giannella RA, Bean J et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect. Immun. 70(4), 1965-1970 (2002).
144. Coster TS, Wolf MK. Immune response, ciprofloxacin activity, and gender differences after human experimental challenge by two strains of enterotoxigenic Escherichia coli. Infect. Immun. 75(1), 252-259 (2007).
145. de Kluijver J, Grunberg K, Sont JK et al. Rhinovirus infection in nonasthmatic subjects: effects on intrapulmonary airways. Eur. Respir. J. 20(2), 274-279 (2002).
146. Doyle WJ, Seroky JT, Angelini BL, Gulhan M, Skoner DP, Fireman P. Abnormal middle ear pressures during experimental influenza A virus infection - role of eustachian tube function. Auris Nasus Larynx 27(4), 323-326 (2000).
147. Doyle WJ, Gentile DA, Cohen S. Emotional style, nasal cytokines, and illness expression after experimental rhinovirus exposure. Brain Behav. Immun. 20(2), 175-181 (2006).
148. Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74(10), 5933-5942 (2006). Well-described malaria challenge that had a Data Safety Monitoring Board and cited Good Clinical Practice.
149. Epstein JE, Rao S, Williams F et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J. Infect. Dis. 196(1), 145-154 (2007).
150. Fidel PL Jr, Barousse M, Espinosa T et al. An intravaginal live Candida challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. Infect. Immun. 72(5), 2939-2946 (2004).
151. Fireman P. Virus-provoked rhinitis in patients who have allergies. Allergy Asthma Proc. 23(2), 99-102 (2002).
152. Fulcher RA, Cole LE, Janowicz DM et al. Expression of Haemophilus ducreyi collagen binding outer membrane protein NcaA is required for virulence in swine and human challenge models of chancroid. Infect. Immun. 74(5), 2651-2658 (2006).
153. Graham DY, Opekun AR, Osato MS et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 53(4), 1235-1243 (2004).
154. Hamrick TS, Dempsey JAF, Cohen MS, Cannon JG. Antigenic variation of gonococcal pilin expression in vivo: analysis of the strain FA1090 pilin repertoire and identification of the pilS gene copies recombining with pilE during experimental human infection. Microbiology 147(4), 839-849 (2001).
155. Hayden FG, Jennings L, Robson R et al. Oral oseltamivir in human experimental influenza B infection. Antiviral Ther. 5(3), 205-213 (2000).
156. Hayden FG, Turner RB, Gwaltney JM et al. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 47(12), 3907-3916 (2003).
157. Iyer GR, Liao S, Massarella J. Population analysis of the pharmacokinetics and pharmacodynamics of RWJ-270201 (BCX-1812) in treating experimental influenza A and B virus in healthy volunteers. AAPS PharmSci. 4(4), 1-10 (2002).
158. Janowicz DM, Tenner-Racz K, Racz P et al. Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication. J. Infect. Dis. 195(10), 1443-1451 (2007).
159. Janowicz DM, Ofner S, Katz BP, Spinola SM. Experimental infection of human volunteers with Haemophilus ducreyi: fifteen years of clinical data and experience. J. Infect. Dis. 199(11), 1671-1679 (2009). Interesting review of human challenge studies using Haemophilus ducreyi.
160. Kester KE, McKinney DA, Tornieporth N et al. A Phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 25(29), 5359-5366 (2007).
161. Landmann JK, Prociv P. Experimental human infection with the dog
162. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res. 63(3), 191-196 (2004).
163. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes Infect. 3(14-15), 1271-1279 (2001).
164. + regulatory T cells in suppression of host responses to Haemophilus ducreyi during experimental infection of human volunteers. J. Infect. Dis. 201(12), 1839-1848 (2010).
165. Lichtenstein DL, Wold WSM. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 11(12), 819-829 (2004).
166. Lyke KE, Laurens M, Adams M et al. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS ONE 5(10), E13490 (2010). Comprehensive reporting of methodology for malaria human challenge experiments.
167. Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir. Res. 7, 116-126 (2006).
168. McCool TL, Cate TR, Moy G, Weiser JN. The immune response to pneumococcal proteins during experimental human carriage. J. Exp. Med. 195(3), 359-365 (2002).
169. McKean MC, Leech M, Lambert PC, Hewitt C, Myint S, Silverman M. A model of viral wheeze in nonasthmatic adults: symptoms and physiology. Eur. Respir. J. 18(1), 23-32 (2001).
170. Muether PS, Gwaltney JM Jr. Variant effect of first- and second-generation antihistamines as clues to their mechanism of action on the sneeze reflex in the common cold. Clin. Infect. Dis. 33(9), 1483-1488 (2001).
171. Nyunt MM, Hendrix CW, Bakshi RP, Kumar N, Shapiro TA. Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am. J. Trop. Med. Hyg. 80(4), 528-535 (2009).
172. Peterson KM, O'Shea M, Stam W, Mohede IC, Patrie JT, Hayden FG. Effects of dietary supplementation with conjugated linoleic acid on experimental human rhinovirus infection and illness. Antiviral Ther. 14(1), 33-43 (2009).
173. Pitisuttithum P, Cohen MB, Phonrat B et al. A human volunteer challenge model using frozen bacteria of the new epidemic serotype, V. cholerae O139 in Thai volunteers. Vaccine 20(5-6), 920-925 (2001).
174. Prendergast MM, Tribble DR, Baqar S et al. In vivo phase variation and serologic response to lipooligosaccharide of Campylobacter jejuni in experimental human infection. Infect. Immun. 72(2), 916-922 (2004).
175. Proud D, Turner RB, Winther B et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am. J. Respir. Crit. Care Med. 178(9), 962-968 (2008).
176. Roestenberg M, McCall M, Mollnes TE et al. Complement activation in experimental human malaria infection. Trans. R. Soc. Trop. Med. Hyg. 101(7), 643-649 (2007).
177. Runeman B, Faergemann J, Larko O. Experimental Candida albicans lesions in healthy humans: dependence on skin pH. Acta Derm. Venereol. 80(6), 421-424 (2000).
178. Spinola SM, Bong CTH, Faber AL et al. Differences in host susceptibility to disease progression in the human challenge model of Haemophilus ducreyi infection. Infect. Immun. 71(11), 6658-6663 (2003).
179. Taylor DN, McKenzie R, Durbin A et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin. Infect. Dis. 42(9), 1283-1288 (2006).
180. Treanor JJ, Kotloff KL, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18(9-10), 899-906 (2000).
181. Tribble DR, Baqar S, Carmolli MP et al. Campylobacter jejuni strain CG8421: a refined model for the study of campylobacteriosis and evaluation of Campylobacter vaccines in human subjects. Clin. Infect. Dis. 49(10), 1512-1519 (2009). Very well-written recent article describing the Campylobacter challenge model.
182. Tribble DR, Baqar S, Scott DA et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect. Immun. 78(4), 1750-1759 (2010).
183. Trobos M, Lester CH, Olsen JE, Frimodt-Moller N, Hammerum AM. Natural transfer of sulphonamide and ampicillin resistance between Escherichia coli residing in the human intestine. J. Antimicrob. Chemother. 63(1), 80-86 (2009).
184. Verhage DF, Telgt DS, Bousema JT et al. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth. J. Med. 63(2), 52-58 (2005).
185. Wright V, Bickle Q. Immune responses following experimental human hookworm infection. Clin. Exp. Immunol. 142(2), 398-403 (2005).
186. Schulz KF, Altman DG, Moher D; for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J. Clin. Epi. 63(8), 834-840 (2010).
187. Boutron I, Moher D, Altman DG, Shulz KF, Ravaud P. Methods and processes of the CONSORT group: example of an extension for trials assessing nonpharmacologic treatments. Ann. Intern. Med. 148(4), W60-W66 (2008).
188. O'Connor AM, Sargeant JM, Gardner IA et al. The REFLECT statement: methods and processes of creating Reporting Guidelines For Randomized Control Trials for livestock and food safety. Prev. Vet. Med. 93(1), 11-18 (2010).
189. The Academy of Medical Sciences (AMS). Microbial Challenge Studies of Human Volunteers. www.acmedsci.ac.uk/p48prid2.html General guidelines for performing human challenge studies with any pathogen.
190. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Higgins JPT & Green S (Eds) (2011). www.cochrane-handbook.org
191. Health Canada. Good Clinical Practice: Consolidated Guideline. www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ich/efficac/e6-eng. php
192. The National Commission for the Protection of Human Subjects of Biomedical and Behavioural Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. http://ohsr.od.nih.gov/guidelines/belmont.html
193. International Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to Biomedical Journals. www.icmje.org/ethical- 6protection.html
194. The CONSORT Group. How CONSORT began. www.consort-statement.org/about- consort/history
195. Health Canada. Good Manufacturing Practices Guidelines. www.hc-sc.gc.ca/dhp-mps/compli-conform/gmp-bpf/index-eng.php
196. Canadian Institutes of Health Research. Knowledge Translation - Definition. www.cihr-irsc.gc.ca/e/39033.html